During diabetes, inhibition of miR-22-3p increases claudin-1 and -3 expression by directly targeting Sp1, resulting in lower epithelial paracellular permeability in SMG epithelial cells, which might contribute to the dysfunction of the diabetic SMG. The gene discussed is SP1; the disease is diabetes mellitus.